TLR3 agonists and proinflammatory antitumor activities

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 5, 2013, Pages 481-483

  Sharma, Sherven ^a,b   Zhu, Li ^a,b   Davoodi, Michael ^a,b   Harris White, Marni ^b   Lee, Jay M ^a   St John, Maie ^a   Salgia, Ravi ^c   Dubinett, Steven ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer; Immune suppression; Immune therapy; TLR3 agonists

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HILTONOL; MONTANIDE ISA 51; NY ESO 1 ANTIGEN; RINTATOLIMOD; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL MATURATION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; EPITHELIUM CELL; FIBROBLAST; GLIOBLASTOMA; HIGH RISK PATIENT; HUMAN; INNATE IMMUNITY; INTERFERON PRODUCTION; MELANOMA; REVIEW; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; HUMANS; NEOPLASMS; TOLL-LIKE RECEPTOR 3;

EID: 84876238309     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.781585     Document Type: Review

References (17)

1. Matsumoto M, Funami K, Tanabe M, et al. Subcellular localization of toll-like receptor 3 in human dendritic cells. J Immunol 2003;171(6):3154-62
2. Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity 2007;27(3):370-83
3. Cheng YS, Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 2010;10(12):1219-23
4. Cheadle EJ, Jackson AM. Bugs as drugs for cancer. Immunology 2002;107(1):10-19
5. Chin AI, Miyahira AK, Covarrubias A, et al. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res 2010;70(7):2595-603
6. Paone A, Starace D, Galli R, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008;29(7):1334-42
7. Salaun B, Coste I, Rissoan MC, et al. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176(8):4894-901
8. Van DN, Roberts CF, Marion JD, et al. Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. FASEB J 2012;26(8):3188-98
9. Inao T, Harashima N, Monma H, et al. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer. Breast Cancer Res Treat 2012;134(1):89-100
10. Nomi N, Kodama S, Suzuki M. Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol Rep 2010;24(1):225-31
11. Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer. J Immunol 2012;188(11):5357-64
12. Wang C, Zhuang Y, Zhang Y, et al. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 2012;30(32):4790-9
13. Robinson RA, DeVita VT, Levy HB, et al. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 1976;57(3):599-602
14. Hawkins MJ, Levin M, Borden EC. An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma. J Biol Response Mod 1985;4(6):664-8
15. Butowski N, Lamborn KR, Lee BL, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 2009;91(2):183-9
16. Strayer DR, Carter WA, Brodsky I, et al. A controlled clinical trial with a specifically configured RNA drug, poly (I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18(Suppl 1):S88-95
17. Shime H, Matsumoto M, Oshiumi H, et al. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci USA 2012;109(6):2066-71